medicina61巻8号

2024年07月発行

特集 “とりあえずスタチン”から脱却！—動脈硬化性疾患一次予防・最新の考え方 トピックス

NAFLD（MASLD）とNASH（MASH）

著者： 吉田博¹

所属機関： ¹東京慈恵会医科大学附属柏病院中央検査部

ページ範囲：P.1328 - P.1334

Point
◎非アルコール性脂肪性肝疾患（NAFLD）と非アルコール性脂肪肝炎（NASH）は代謝異常を組み入れてMASLDとMASHに名称が変更された．
◎NAFLD（MASLD）は高トリグリセライド（TG）血症，高LDLコレステロール（LDL-C）血症，低HDLコレステロール（HDL-C）血症と関連する．
◎NAFLD（MASLD）患者では，動脈硬化惹起性の高いsd-LDLやレムナントリポ蛋白コレステロールが増加する．
◎NAFLD（MASLD）/NASH（MASH）患者では，非NAFLD（MASLD）患者と比較し，動脈硬化性心血管疾患（ASCVD）の発症リスクおよび死亡リスクが高い．

参考文献

1）Okamura T, et al：Japan Atherosclerosis Society（JAS）guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb Online ahead of print, 2023 PMID 38123343

2）日本動脈硬化学会（編）：動脈硬化性疾患予防ガイドライン2022年版，日本動脈硬化学会，2022

3）Ludwig J, et al：Nonalcoholic steatohepatitis；Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55：434-438, 1980 PMID 7382552

4）Tokushige K, et al：Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 56：951-963, 2021 PMID 34533632

5）Eslam M, et al：MAFLD；A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158：1999-2014.e1, 2020 PMID 32044314

6）Eslam M, et al：A new definition for metabolic dysfunction-associated fatty liver disease；An international expert consensus statement. J Hepatol 73：202-209, 2020 PMID 32278004

7）Rinella ME, et al；NAFLD Nomenclature consensus group：A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79：1542-1556, 2023 PMID 37364790

8）Duell PB, et al：Nonalcoholic fatty liver disease and cardiovascular risk；A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 42：e168-e185, 2022 PMID 35418240

9）Tokushige K：New concept in fatty liver diseases. Hepatol Res 54：125-130, 2024 PMID 38146790

10）Tokushige K, et al：Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 56：951-963, 2021 PMID 34533632

11）Hamaguchi M, et al：The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143：722-728, 2005 PMID 16287793

12）Fujii H, et al：Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan；A large-scale multicenter retrospective study. Hepatol Res 53：1059-1072, 2023 PMID 37537735

13）En Li Cho E, et al：Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus；An updated systematic review and meta-analysis. Gut 72：2138-2148, 2023 PMID 37491159

14）Nakahara T, et al；Japan Study Group of Nonalcoholic Fatty Liver Disease：Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 49：1477-1484, 2014 PMID 24277052

15）Imajo K, et al：LDL-migration index（LDL-MI）, an indicator of small dense low-density lipoprotein（sdLDL）, is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver；A multicenter cross-sectional study. PLoS One 9：e115403, 2014 PMID 25541989

16）Campanella A, et al：The effect of three Mediterranean diets on remnant cholesterol and non-alcoholic fatty liver disease；A secondary analysis. Nutrients 12：1674, 2020 PMID 32512752

17）Musso G, et al：Meta-analysis；Natural history of non-alcoholic fatty liver disease（NAFLD）and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43：617-649, 2011 PMID 21039302

18）Targher G, et al：Non-alcoholic fatty liver disease and risk of incident cardiovascular disease；A meta-analysis. J Hepatol 65：589-600, 2016 PMID 27212244

19）Simon TG, et al：Mortality in biopsy-confirmed nonalcoholic fatty liver disease；Results from a nationwide cohort. Gut 70：1375-1382, 2021 PMID 33037056

20）Wu S, et al：Association of non-alcoholic fatty liver disease with major adverse cardiovascular events；A systematic review and meta-analysis. Sci Rep 6：33386, 2016 PMID 27633274

21）Puchner SB, et al：High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden；Results from the ROMICAT Ⅱ trial. Radiology 274：693-701, 2015 PMID 25369449

22）Sung KC, et al：Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification；A cross-sectional and longitudinal cohort study. Arterioscler Thromb Vasc Biol 43：482-491, 2023 PMID 36727522

23）Zhou YY, et al：Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis；A systematic review and meta-analysis. Hepatol Commun 2：376-392, 2018 PMID 29619417

24）Angulo P, et al：Liver fibrosis, but no other histologic features, is associated with long term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149：389-397.e10, 2015 PMID 25935633

25）Wieckowska A, et al：Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis；Present and future. Hepatology 46：582-589, 2007 PMID 17661414

26）Eguchi Y, et al：Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan；A multicenter large retrospective study. J Gastroenterol 47：586-595, 2012 PMID 22328022

27）吉田博：日本医療研究開発機構AMED令和5年度予防・健康づくりの社会実装に向けた研究開発基盤整備事業，脂肪肝関連疾患にともなう動脈硬化性心血管疾患の二次・三次予防に資するヘルスケアサービスの指針策定およびシステム開発に関する研究　https://www.amed.go.jp/koubo/12/02/1202C_00017.html（2024年4月閲覧）

28）Pradhan AD, et al；PROMINENT Investigators：Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 387：1923-1934, 2022 PMID 36342113

29）Yamashita S, et al：Managing hypertriglyceridemia for cardiovascular disease prevention；Lessons from the PROMINENT trial. Eur J Clin Invest：e14227（Online ahead of print）, 2024 PMID 38662591

30）Harrison SA, et al；MAESTRO-NASH Investigators：A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390：497-509, 2024 PMID 38324483